| Population 2015 |
28 million |
| |
| | | | | |
| Estimates of TB burden*, 2015 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
21 |
(12–32) |
74 |
(43–115) |
| Mortality (HIV+TB only) |
34 |
(21–50) |
120 |
(73–178) |
| Incidence (includes HIV+TB) |
154 |
(100–220) |
551 |
(356–787) |
| Incidence (HIV+TB only) |
79 |
(50–115) |
284 |
(179–412) |
| Incidence (MDR/RR-TB)** |
7.3 |
(4.1–10) |
26 |
(15–36) |
| |
| | | | | |
| Estimated TB incidence by age and sex (thousands)*, 2015 |
| |
0-14 years |
> 14 years |
Total |
| Females |
7.4 |
(3–12) |
56 |
(27–86) |
64 |
(30–98) |
| Males |
7.4 |
(4.2–11) |
83 |
(57–108) |
90 |
(62–119) |
| Total |
15 |
(9.2–20) |
139 |
(106–172) |
154 |
(100–220) |
| |
| | | | | |
| TB case notifications, 2015 |
|
| Total cases notified |
61 559 |
| Total new and relapse |
58 344 |
| - % tested with rapid diagnostics at time of diagnosis |
7% |
| - % with known HIV status |
99% |
| - % pulmonary |
89% |
| - % bacteriologically confirmed among pulmonary |
50% |
| |
| | | | | |
| Universal health coverage and social protection |
|
| TB treatment coverage (notified/estimated incidence), 2015 |
38% (27–59) |
| TB patients facing catastrophic total costs |
|
| TB case fatality ratio (estimated mortality/estimated incidence), 2015 |
0.37 (0.21–0.6) |
| |
| | | | | |
| TB/HIV care in new and relapse TB patients, 2015 |
Number |
(%) |
| Patients with known HIV-status who are HIV-positive |
29 827 |
51% |
| - on antiretroviral therapy |
27 417 |
92% |
| |
| | | | | |
| Drug-resistant TB care, 2015 |
New cases |
Previously treated
cases |
Total
number*** |
Estimated MDR/RR-TB cases among notified
pulmonary TB cases |
|
2 800
(1 700–3 900) |
| Estimated % of TB cases with MDR/RR-TB |
3.7% (2.4–5) |
20% (1.9–37) |
|
| % notified tested for rifampicin resistance |
17% |
31% |
10 937 |
| MDR/RR-TB cases tested for resistance to second-line drugs |
|
195 |
| Laboratory-confirmed cases |
MDR/RR-TB: 646, XDR-TB: 29 |
| Patients started on treatment **** |
MDR/RR-TB: 646, XDR-TB: 16 |
| |
| | | | | |
| Treatment success rate and cohort size |
Success |
Cohort |
| New and relapse cases registered in 2014 |
89% |
55 703 |
| Previously treated cases, excluding relapse, registered in 2014 |
94% |
2 567 |
| HIV-positive TB cases, all types, registered in 2014 |
|
|
| MDR/RR-TB cases started on second-line treatment in 2013 |
52% |
313 |
| XDR-TB cases started on second-line treatment in 2013 |
|
|
| |
| | | | | |
| TB preventive treatment, 2015 |
|
| % of HIV-positive people (newly enrolled in care) on preventive treatment |
45% |
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment |
|
| |
| | | | | |
| TB financing, 2016 |
|
| National TB budget (US$ millions) |
24 |
| Funding source: 4% domestic, 72% international, 24% unfunded |
| |
| | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin | | | |
| *** Includes cases with unknown previous TB treatment history | | | | |
| **** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed | | |
| | | | | |